Sign in
CompletedNo phase

Heparin Like Effect in Acute Variceal Bleeding

Key facts

Who runs it
Post Graduate Institute of Medical Education and Research, Chandigarh
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
93 people enrolled
Started
1 Nov 2019
Ended
30 Sept 2026
Type of study
Observational, 2 groups
Treatments tested
  • SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
Record updated
13 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Age 18-65 years
  • Cirrhosis with acute variceal bleeding

Who cannot take part

  • Current therapy: Recent blood or blood component transfusion in the last 2 weeks
  • Patients requiring antiplatelet therapy,
  • HIV positive/ AIDS patients
  • Renal insufficiency requiring dialysis
  • Active malignancy within the last 5 years
  • Patient with other neurological disease and metabolic disorders, unbalanced heart failure and/or respiratory failure or end-stage renal disease
  • Patients with evidence of sepsis at presentation
  • Administration of anticoagulants, antifibrinolytics,
  • Not willing to participate in the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study attempts to clarify the pathophysiology of haemostasis in relation to the evidence of sepsis in liver disease, and compares the accuracy of various available laboratory tests in assessment of these patients. Further research is needed for proper understanding of the influence of sepsis on coagulation disorders in acute variceal bleeding in cirrhosis, to correctly identify the type and optimal quantity of blood product requirement in at risk patients.

Read full original descriptionShow less

Thromboelastography (TEG) /Sonoclot has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products. Secondly, the study of derangement in coagulopathy after the onset of sepsis is of paramount importance because of increased mortality after the onset of sepsis. In the present study, patients with cirrhosis who present with acute variceal bleeding, will be included in the study cohort, and will undergo a baseline diagnostic workup as described. They will be followed for development of any signs of infection after hospitalization. Then the effect of sepsis on their coagulation and thrombin generation response swill be assessed. Thus the effect of sepsis on the progression and outcome of coagulopathy in patients with acute variceal bleeding will be studied.

The 2 groups in the trial

  • Cirrhosis with variceal bleeding

    Coagulation factor assays and heparinase treated SONOCLOT at Days 0,3, and 7

    Treatment: SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI

  • Cirrhosis without Bleeding

    Control group of 25 subjects

    Treatment: SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Coagulation Profile and Role of Endogenous Heparinoids in SIRS and Sepsis in Acute Variceal Bleeding in Cirrhosis
Publications
Record updated
13 November 2026